Humanigen appoints Timothy Morris as Chief Operating Officer and Chief Financial Officer
Humanigen have appointed Timothy E. Morris to its newly created role of Chief Operating Officer and Chief Financial Officer and he will report to the Chief Executive Officer, Dr Cameron Durrant.
Morris has over two decades of experience serving in executive roles in biotech. He recently served as the Chief Financial Officer of Lovance and has been on the Board of Directors at Humanigen since 2016. He has now stepped down from the Board while assuming his new positions.
Discussing his new roles, Morris said: “I am honored to join the Humanigen management team and look forward to helping advance our pivotal Phase III clinical trial for lenzilumab in COVID-19 patients as we plan for registration and potential commercialization, as well as continue to accelerate our deep pipeline.”
The CEO Cameron Durrant also spoke on Morris’s appointment, saying: “We are delighted that Tim has joined our leadership team at such an important time for the company,” said Dr. Durrant. “We believe that his track record of accomplishments, combined with his capital markets expertise and extensive knowledge of the company, will be indispensable as Humanigen prepares for its next phase of growth as a potential commercial organization.”